NASDAQ:EXAS Exact Sciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. $41.13 +1.74 (+4.42%) (As of 07/1/2022 03:59 PM ET) Add Compare Share Today's Range$39.66▼$41.5050-Day Range$35.61▼$62.5252-Week Range$35.34▼$125.00Volume92,549 shsAverage Volume2.16 million shsMarket Capitalization$7.24 billionP/E RatioN/ADividend YieldN/APrice Target$101.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Exact Sciences MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside146.4% Upside$101.33 Price TargetShort InterestHealthy6.22% of Shares Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.54Based on 9 Articles This WeekInsider TradingSelling Shares$43,581 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.25) to ($3.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.36 out of 5 starsMedical Sector156th out of 1,428 stocksMedical Laboratories Industry3rd out of 32 stocks 3.4 Analyst's Opinion Consensus RatingExact Sciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $101.33, Exact Sciences has a forecasted upside of 146.4% from its current price of $41.13.Amount of Analyst CoverageExact Sciences has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.22% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Exact Sciences has recently decreased by 5.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Previous Next 3.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExact Sciences has received a 65.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private colorectal cancer diagnostics services" product. See details.Environmental SustainabilityThe Environmental Impact score for Exact Sciences is -0.66. Previous Next 3.1 News and Social Media Coverage News SentimentExact Sciences has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Exact Sciences this week, compared to 2 articles on an average week.Search Interest18 people have searched for EXAS on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.MarketBeat Follows23 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 35% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,581.00 in company stock.Percentage Held by InsidersOnly 1.40% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions94.45% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($4.25) to ($3.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -9.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -9.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About Exact Sciences (NASDAQ:EXAS) StockExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Read More EXAS Stock News HeadlinesJuly 4, 2022 | americanbankingnews.comExact Sciences Co. (NASDAQ:EXAS) Director Katherine S. Zanotti Sells 1,086 SharesJuly 3, 2022 | americanbankingnews.comHead-To-Head Review: Biocept (NASDAQ:BIOC) vs. Exact Sciences (NASDAQ:EXAS)July 1, 2022 | americanbankingnews.comAnalysts Set Exact Sciences Co. (NASDAQ:EXAS) Price Target at $105.85June 30, 2022 | finance.yahoo.comExact Sciences (EXAS) Cologuard Growth Robust Amid Margin WoesJune 24, 2022 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Downgraded to Sell at StockNews.comJune 22, 2022 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) vs. Vyant Bio (NASDAQ:VYNT) Critical ComparisonJune 21, 2022 | nasdaq.comUltima Genomics, Exact Sciences In Deal To Improve Patient Access To Genomics-based TestingJune 21, 2022 | finance.yahoo.comUltima Genomics and Exact Sciences enter long-term supply agreement aimed at improving patient access to genomic testing by driving down sequencing costsJune 13, 2022 | nasdaq.comRSI Alert: EXACT Sciences (EXAS) Now OversoldJune 13, 2022 | thestreet.comExact Sciences CorporationJune 9, 2022 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Sets New 12-Month Low at $45.37June 3, 2022 | markets.businessinsider.comExpert Ratings for Exact SciencesMay 27, 2022 | finance.yahoo.comExact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations at ASCO 2022May 26, 2022 | finance.yahoo.comWhy Is Exact Sciences (EXAS) Down 22.5% Since Last Earnings Report?May 26, 2022 | nasdaq.comEXAS July 8th Options Begin TradingMay 14, 2022 | seekingalpha.comExact Sciences: Sell-Off Provides An Opportunity To Buy At A Reasonable ValuationMay 12, 2022 | nasdaq.comJuly 1st Options Now Available For EXACT SciencesMay 6, 2022 | finance.yahoo.comIllumina Stock Plunges Despite Strong Results, Gene-Sequencing SalesApril 28, 2022 | nasdaq.comEXAS June 10th Options Begin TradingApril 28, 2022 | finance.yahoo.comUpdated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer PatientsApril 27, 2022 | nasdaq.comNotable Wednesday Option Activity: QCOM, EXAS, TAApril 27, 2022 | markets.businessinsider.comSVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To KnowApril 27, 2022 | finance.yahoo.comHow Exact Sciences Aims to Keep Its Lead in Cancer TestsApril 27, 2022 | finance.yahoo.comNon-COVID Sales Boost Exact Sciences' Q1 Revenue; Revises FY22 GuidanceApril 27, 2022 | finance.yahoo.comExact Sciences (EXAS) Q1 Earnings Top Estimates, Sales View UpSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,500Year Founded1995Company Calendar Last Earnings4/26/2022Today7/04/2022Next Earnings (Estimated)7/27/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$101.33 High Stock Price Forecast$155.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+146.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($4.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-595,630,000.00 Net Margins-40.26% Pretax Margin-40.59% Return on Equity-21.82% Return on Assets-11.23% Debt Debt-to-Equity Ratio0.67 Current Ratio2.53 Quick Ratio2.29 Sales & Book Value Annual Sales$1.77 billion Price / Sales4.10 Cash FlowN/A Price / Cash FlowN/A Book Value$19.66 per share Price / Book2.09Miscellaneous Outstanding Shares175,945,000Free Float173,482,000Market Cap$7.24 billion OptionableOptionable Beta1.31 Social Links Exact Sciences Frequently Asked Questions Should I buy or sell Exact Sciences stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Exact Sciences stock. View analyst ratings for Exact Sciences or view top-rated stocks. What is Exact Sciences' stock price forecast for 2022? 12 analysts have issued 12 month price targets for Exact Sciences' shares. Their EXAS stock forecasts range from $50.00 to $155.00. On average, they expect Exact Sciences' stock price to reach $101.33 in the next twelve months. This suggests a possible upside of 146.4% from the stock's current price. View analysts' price targets for Exact Sciences or view top-rated stocks among Wall Street analysts. How has Exact Sciences' stock performed in 2022? Exact Sciences' stock was trading at $77.83 at the beginning of 2022. Since then, EXAS stock has decreased by 47.2% and is now trading at $41.13. View the best growth stocks for 2022 here. When is Exact Sciences' next earnings date? Exact Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for Exact Sciences. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) released its earnings results on Tuesday, April, 26th. The medical research company reported ($1.04) EPS for the quarter, beating analysts' consensus estimates of ($1.12) by $0.08. The medical research company earned $486.57 million during the quarter, compared to the consensus estimate of $461.86 million. Exact Sciences had a negative trailing twelve-month return on equity of 21.82% and a negative net margin of 40.26%. During the same quarter in the previous year, the company posted ($0.18) EPS. View Exact Sciences' earnings history. What guidance has Exact Sciences issued on next quarter's earnings? Exact Sciences updated its FY 2022 earnings guidance on Tuesday, April, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.99 billion-$2.03 billion, compared to the consensus revenue estimate of $2.01 billion. Who are Exact Sciences' key executives? Exact Sciences' management team includes the following people: Mr. Kevin T. Conroy, Chairman of The Board & CEO (Age 56, Pay $2.37M) (LinkedIn Profile)Mr. Jeffrey T. Elliott CFA, Exec. VP, CFO & COO (Age 44, Pay $904.67k)Mr. D. Scott Coward, Chief Legal Officer (Age 57, Pay $847.28k)Mr. Graham P. Lidgard, Emeritus Chief Science Officer (Age 73, Pay $937.04k) (LinkedIn Profile)Mr. Everett V. Cunningham, Chief Commercial Officer (Age 56, Pay $1.01M)Mr. Jake Orville, Gen. Mang. of Pipeline (Age 48, Pay $720.45k)Mr. Gary Frings, Chief Information OfficerDr. Jorge A. Garces Ph.D., Chief Science Officer (Age 50)Ms. Megan Jones, Associate Mang. of Investor RelationsMr. Tim Caprez, Chief Compliance Counsel & VP What is Kevin T. Conroy's approval rating as Exact Sciences' CEO? 141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Exact Sciences' key competitors? Some companies that are related to Exact Sciences include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO) and Ionis Pharmaceuticals (IONS). View all of EXAS's competitors. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV). What is Exact Sciences' stock symbol? Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS." How do I buy shares of Exact Sciences? Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exact Sciences' stock price today? One share of EXAS stock can currently be purchased for approximately $41.13. How much money does Exact Sciences make? Exact Sciences (NASDAQ:EXAS) has a market capitalization of $7.24 billion and generates $1.77 billion in revenue each year. The medical research company earns $-595,630,000.00 in net income (profit) each year or ($4.32) on an earnings per share basis. How many employees does Exact Sciences have? Exact Sciences employs 6,500 workers across the globe. Does Exact Sciences have any subsidiaries? The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..Read More When was Exact Sciences founded? Exact Sciences was founded in 1995. How can I contact Exact Sciences? Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for Exact Sciences is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701. This page (NASDAQ:EXAS) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
